

Statin Therapy Measures Tip Sheet

Statin Therapy for Pts with Diabetes (SPD)

Measure Description: The % of patients 40-75yrs with a diagnosis of Diabetes during the measurement year who do not have Atherosclerotic Cardiovascular Disease (ASCVD). PPO

Measure Goal: Dispensed at least one statin therapy of any intensity during the measurement year.

Inclusion Criteria: Patient medical claim and or pharmacy data. Any LDL result is inclusive.

Statin Therapy for Pts with Cardiovascular Disease (SPC)

Measure Description: The % of males 21-75yrs and females 40-75yrs with a diagnosis Atherosclerotic Cardiovascular Disease (ASCVD). PPO /Medicare

Measure Goal: Dispensed at least one statin therapy of moderate or high intensity during the measurement year.

Inclusion Criteria: Patient with MI, CABG, PCI, or diagnosis of Ischemic Vascular Disease (IVD). Any LDL result is inclusive.

Statin Use for Pts with Diabetes (SUPD)

Measure Description: The % of Medicare patients 40-75yrs with a diagnosis of Diabetes. BCNA/MA PPO

Measure Goal: Dispensed at least one statin therapy med of any intensity during the measurement year.

Inclusion Criteria: Patient medical pharmacy claim data only (at least 2 diabetes medication fills)

Moderate Intensity Statin

Name of Drug	Dosage
Atorvastatin (Lipitor)	10-20 mg
Amlodipine-atorvastatin (Caduet)	10-20 mg
Ezetimibe-simvastatin (Vytorin)	20-40 mg
Fluvastatin (Lescol)	40-80 mg
Lovastatin (Mevacor)	40 mg
Pitavastatin (Livalo)	2-4 mg
Pravastatin (Pravachol)	40-80 mg
Rosuvastatin (Crestor)	5-10 mg
Simvastatin (Zocor)	20-40 mg

High Intensity Statin

Name of Drug	Dosage
Atorvastatin	40-80 mg
Amlodipine-atorvastatin	40-80 mg
Ezetimibe-simvastatin	80 mg
Rosuvastatin	20-40 mg
Simvastatin	80mg

Medications Excluded: Zetia, Repatha and Praluent

Codes to submit for Statin Intolerance (Use for SPD & SPC only)

Exclusion Criteria: Cirrhosis, Myalgia, Myositis, Myopathy, Rhabdomyolysis, ESRD, Pregnant, ≥66 living in institutional or SNF setting, ≥81 with frailty claim, dispensed dementia medication and hospice.

Cirrhosis

K70.30 Alcoholic cirrhosis of liver w/o ascites
K70.31 Alcoholic cirrhosis of liver w/ascites
K71.7 Toxic liver w/fibrosis & cirrhosis of liver
K74.3 Primary biliary cirrhosis
K74.4 Secondary biliary cirrhosis
K74.5 Biliary cirrhosis, unspecified
K74.60 Unspecified cirrhosis of liver
K74.69 Other cirrhosis of liver
P78.81 Congenital cirrhosis (of liver)
K70.0 Alcoholic fatty liver
K70.9 Alcoholic liver disease unspecified

Muscular Pain & Disease

G72.0 Drug induced myopathy
G72.2 Myopathy due to other toxic agents
G72.9 Myopathy, unspecified
M60.80 Other myositis, unspecified site
M60.89 Other myositis, multiple sites
M60.9 Myositis, unspecified
M62.82 Rhabdomyolysis
M79.1 Myalgia
M79.10 Myalgia, unspecified site
M79.18 Myalgia, other site
G72.89 Other specified myopathies
T46.6X5A Adverse effect of Antihyperlipidemic & antiarteriosclerotic drug initial encounter (SUPD only)

End Stage Renal Disease

N18.5 Chronic Kidney Disease, stage 5
N18.6 End Stage Renal Disease
Z99.2 Dependence on Renal Dialysis